PARP Inhibitors Show Significant Progression-Free Survival Benefits in Ovarian Cancer Despite Increased Severe Adverse Events
A comprehensive Cochrane review of 15 randomized trials involving 6109 women evaluated the clinical impact of PARP inhibitors across newly ...
Read moreDetails